Stacey Crane
PhD, RN, CPON
Assistant Professor
Department of Research
Stacey Crane PhD RN CPON, is a PARTNERS Research Scholar with 13 years of experience as a pediatric oncology bedside nurse and clinical trial research nurse. These clinical experiences solidified her passion to conduct research that will make a difference in the lives of children with cancer and their families, and that will honor their treatment decisions and support their quality of life. While Dr. Crane’s master’s studies focused on Nursing Informatics, her doctoral and post-doctoral training was focused on behavioral research and was fully funded by the NIH (T32 NR007066, F31 NR015393, and T32 CA117865). During her doctoral studies, she also received a graduate certificate in bioethics, with a focus on research ethics. Her doctoral dissertation, “Parents’ Experiences in Phase I Pediatric Oncology Clinical Trials”, was recognized with two Outstanding Dissertation Awards from the Midwest Nursing Research Society. Dr. Crane is an active member of the Children’s Oncology Group, the Association of Pediatric Hematology and Oncology Nurses, and the Southern Nursing Research Society.
Education
Indiana University – Purdue University Indianapolis, Indianapolis, Indiana
Doctor of Philosophy in Nursing
Oct 2017
Indiana University – Purdue University Indianapolis, Indianapolis, Indiana
Graduate Certificate in Bioethics
August 2015
Chamberlain College of Nursing, Columbus, Ohio
Master of Science in Nursing – Nursing Informatics
May 2013
Ryerson University, Toronto, Ontario
Bachelor of Science in Nursing
May 2001
Clinical/Research Focus
Dr. Stacey Crane’s overarching research goal is to improve the outcomes of children with cancer by enhancing the care provided to children receiving precision oncology therapies and participating in early phase clinical trials. This research trajectory was directly informed by her experiences caring for children with cancer and their families.
Dr. Crane is currently focused on developing and testing an innovative interface that will enable children with cancer or their parents to report the child's symptoms during cancer treatment in a more comprehensive, accurate manner, but without undue burden. This novel interface uses items from the Pediatric Patient Reported Outcome Common Terminology Criteria for Adverse Events (Pediatric PRO-CTCAE) to assess subjective symptomatic toxicities. The intent is for the interface to facilitate broader surveillance for symptom trends and drug toxicities, not only for children participating in clinical trials but also for precision oncology therapies and other treatments given outside of clinical trials.
